20多年来，罗氏致力于为血液病患者开发药物，在这一治疗领域积累了丰富的经验与知识。现如今，罗氏的投入远超以往，努力为各类血液病患者提供创新的治疗选择。目前公司获批的药物包括美罗华^{®<\/sup>（利妥昔单抗）、佳罗华^{®<\/sup>（奥妥珠单抗）、优罗华^{®<\/sup>（维泊妥珠单抗）、高罗华^{®<\/sup>（格菲妥单抗）和舒友立乐^{®<\/sup>（艾美赛珠单抗）；另外还包括淋巴瘤创新药 Mosunetuzumab（CD20xCD3 T细胞-双特异性抗体）和Crovalimab（可伐利单抗）。罗氏的科学专业知识，加上广泛的产品组合和产品线，也为开发进一步改善患者生活的联合治疗方案提供了独特的机会。<\/p> \n}}}}}

罗氏是一家全球领先的生物技术企业，总部在瑞士，拥有125余年悠久历史。结合制药和诊断两大领域的独特优势，我们致力于通过个体化医疗推动科学进步，改善人类生活。作为全球制药和诊断领域的领导者，罗氏在抗肿瘤、免疫、抗感染、眼科和神经科学系统领域拥有一流的差异化药物。创新是罗氏的DNA。作为一家以创新为驱动的制药公司，每年，罗氏集团在研发创新领域投入巨大。2021年，罗氏全球的研发投入达到150亿美元，约占公司收入的20%。<\/p> \n

\n \n \n \n \n \n \n \n
^{[1] <\/sup>Roche. FDA approves Roche’s Columvi, the first and only bispecific antibody with a fixed-duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma. 2023. https:\/\/www.roche.com\/media\/releases\/med-cor-2023-06-16<\/a><\/span><\/p> <\/td> \n <\/tr> \n}
^{[2] <\/sup>Coiffier B, et al. Blood. 2010;116(12):2040-2045.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[3] <\/sup>Varma G, Goldstein J, Advani RH. Novel agents in relapsed\/refractory diffuse large B-cell lymphoma. Hematol Oncol. 2023;41 Suppl 1:92-106.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[4] <\/sup>Hutchings M, et al. Glofitamab monotherapy in patients with relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL):extended follow-up and landmark analyses from a pivotal phase II study. 2023 ASCO Poster 7550; 2023 EHA. Poster 1129; 2023 ICML Oral 95.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[5] <\/sup>Song YQ, et al. Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2023 Oct 19. doi: 10.3324\/haematol.2023.283802. Epub ahead of print.<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n}
<\/p>"]; $("#dvExtra").html(content_array[0]);})();